Zobrazeno 1 - 10
of 21
pro vyhledávání: '"G. M. TELETAEVA"'
Autor:
E. A. Ulrikh, E. L. Dikareva, A. D. Dzharbaeva, O. A. Zhamborova, T. M. Pervuninа, E. V. Komlichenko, S. A. Protsenko, G. M. Teletaeva, O. A. Li, A. S. Artemyeva, I. A. Mashenko, G. F. Kutusheva, T. Yu. Semiglazova, А. F. Urmancheeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 3, Pp 112-117 (2022)
Trophoblastic neoplasias are rare tumors, accounting for less than 1 % of malignant neoplasms of the female genital tract. Trophoblastic tumors associated with developing pregnancy are extremely rare. The article presents the successful experience of
Externí odkaz:
https://doaj.org/article/aca41088b8854a62a107554883917393
Autor:
E. A. Degtiareva, S. A. Protsenko, E. N. Imyanitov, G. M. Teletaeva, D. Kh. Latipova, A. I. Semenova, A. V. Novik
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 5, Pp 162-167 (2022)
Background. The development of unique immune-related adverse events (irAEs) is a known hallmark of immunotherapy. Generally, such complications occur during the first 3–6 months of immunotherapy, however, the experience with immune checkpoint inhib
Externí odkaz:
https://doaj.org/article/cfda88e2472c45b3aad1f09ca00782ed
Autor:
G. M. Teletaeva, E. A. Ulrikh, D. Kh. Latipova, A. I. Semenova, E. V. Levchenko, D. G. Ulrikh, I. V. Berlev, T. Yu. Semiglazova, S. A. Protsenko, A. F. Urmancheeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 3, Pp 67-71 (2021)
Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and
Externí odkaz:
https://doaj.org/article/60736af458fb4801999c1654f4987569
Autor:
N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 165-174 (2020)
Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucir
Externí odkaz:
https://doaj.org/article/c36b27f6439d4e80b0427ab6e064acee
Autor:
N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 104-113 (2019)
Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced g
Externí odkaz:
https://doaj.org/article/585c4f001e1d4aa6b26c7d34d605422b
Autor:
Z. S. Kotova, T. Yu. Semiglazova, I. A. Baldueva, D. H. Latipova, D. O. Yurlov, V. V. Semiglazov, G. M. Teletaeva, A. V. Novik, A. I. Semenova, S. A. Protsenko
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 172-175 (2018)
The aim of this study is to analyse the efficacy of efferent therapy (hemosorption) as part of drug treatment in patients with metastatic colorectal cancer (mCRC) based on the use of standard first-line chemotherapy combined with the bevacizumab bios
Externí odkaz:
https://doaj.org/article/4b8d8806db7444a88919e0781d762df9
Publikováno v:
Опухоли женской репродуктивной системы, Vol 13, Iss 3, Pp 17-27 (2017)
Knowledge of anthracycline antibiotics’ (AAs) pathogenesis and main risk factors allowed to develop various methods of prevention and early detection of cardiotoxicity as well as to create several guidelines on decreasing the risk of its developmen
Externí odkaz:
https://doaj.org/article/04ad606a2b924b988d924a4afe9bdcd9
Autor:
T. Y. SEMIGLAZOVA, V. A. KLYUGE, E. A. KOROBEYNIKOVA, P. V. KRIVOROTKO, R. M. PALTUEV, G. M. TELETAEVA, D. H. LATIPOVA, V. V. KLIMENKO, E. V. TACHENKO, A. V. Novik, A. I. SEMENOVA, V. V. SEMIGLAZOV, S. A. PROTSENKO, V. F. SEMIGLAZOV
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 72-83 (2017)
The review considers information about the efficacy and safety of Ixabepilone as a monotherapy and as a component of combination therapy for advanced breast cancer. Successful treatment of metastatic breast cancer is often confounded by resistance to
Externí odkaz:
https://doaj.org/article/a411c9ac77e14e4eb0bc624119f30783
Autor:
T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 56-65 (2016)
Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treat
Externí odkaz:
https://doaj.org/article/7ac0b7e66bad4bcaa3c872a3ba8a7d62
Autor:
G. M. TELETAEVA, T. Y. SEMIGLAZOVA, А. S. ZHABINA, D. H. LATIPOVA, V. V. KLIMENKO, Z. S. KOTOVA, A. I. SEMENOVA, S. A. PROTSENKO, V. V. SEMIGLAZOV
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 74-83 (2016)
Modern therapeutic approaches allow achieving stable therapeutic effect, extension and maximum long-term preservation of the quality of life of metastatic mammary gland cancer patients. Currently there is no optimal consequence of cytostatic agents u
Externí odkaz:
https://doaj.org/article/89d181bcd2e64ba48715dabe1c38087a